Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Return on Equity (2020 - 2023)

Cullinan Therapeutics has reported Return on Equity over the past 4 years, most recently at 0.32% for Q3 2023.

  • Quarterly results put Return on Equity at 0.32% for Q3 2023, down 49.0% from a year ago — trailing twelve months through Sep 2023 was 0.32% (down 49.0% YoY), and the annual figure for FY2022 was 0.23%, up 44.0%.
  • Return on Equity for Q3 2023 was 0.32% at Cullinan Therapeutics, down from 0.29% in the prior quarter.
  • Over the last five years, Return on Equity for CGEM hit a ceiling of 0.21% in Q2 2022 and a floor of 0.41% in Q4 2020.
  • Median Return on Equity over the past 4 years was 0.15% (2021), compared with a mean of 0.09%.
  • Biggest five-year swings in Return on Equity: soared 35bps in 2022 and later crashed -50bps in 2023.
  • Cullinan Therapeutics' Return on Equity stood at 0.41% in 2020, then surged by 62bps to 0.15% in 2021, then skyrocketed by 226bps to 0.19% in 2022, then tumbled by -266bps to 0.32% in 2023.
  • The last three reported values for Return on Equity were 0.32% (Q3 2023), 0.29% (Q2 2023), and 0.13% (Q1 2023) per Business Quant data.